statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Appointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent DirectorsBoard of Director appointments in conjunction with Avalo's recent acquisition of...

Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

Shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) have earned an average recommendation of "Buy" from the six analysts that are currently covering the firm, Marketbeat reports. Six...

Tourmaline Bio, Inc. (NASDAQ:TRML) Receives $55.60 Consensus Target Price from Analysts

Tourmaline Bio (NASDAQ:TRML  Free Report) had its target price raised by Jefferies Financial Group from $41.00 to $72.00 in a report released on Wednesday morning, Benzinga reports. Jefferies...

Tourmaline Bio (NASDAQ:TRML) Price Target Increased to $72.00 by Analysts at Jefferies Financial Group

Tourmaline Bio, Inc. (NASDAQ:TRML  Get Free Report)s share price gapped down prior to trading on Thursday . The stock had previously closed at $44.67, but opened at $29.29. Tourmaline...

Tourmaline Bio (NASDAQ:TRML) Shares Gap Down to $44.67

Tourmaline Bio, Inc. (NASDAQ:TRML  Free Report)  Equities researchers at Leerink Partnrs upped their Q1 2024 earnings per share estimates for shares of Tourmaline Bio in a research...

Q1 2024 Earnings Estimate for Tourmaline Bio, Inc. Issued By Leerink Partnrs (NASDAQ:TRML)

This is a signal that TRML's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

Tourmaline Bio (TRML, $24.66) RSI Indicator left the oversold zone on March 22, 2024

Tourmaline Bio, Inc. (NASDAQ:TRML  Free Report)  Analysts at HC Wainwright lifted their Q1 2024 earnings per share (EPS) estimates for Tourmaline Bio in a note issued to investors on...

HC Wainwright Equities Analysts Increase Earnings Estimates for Tourmaline Bio, Inc. (NASDAQ:TRML)

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Tourmaline Bio sees cash runway into 2027

Tourmaline Bio reports Q4 EPS (81c) vs. ($5.51) last year

Initiated pivotal spiriTED Phase 2b trial in Thyroid Eye Disease (TED) in 2023 and expanded TED clinical development plan, including accelerating the planned initiation of a pivotal Phase 3 trial...

Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Tourmaline Bio, Inc. is a late-stage clinical biotechnology company, which engages in the development of medicines for patients with life-altering immune diseases. It offers the TOUR006. The company was founded by Sandeep Kulkarni on September 17, 2021 and is headquartered in New York, NY.

Volume	147,739.00
52-Wk High	$48.31
52-Wk Low	$9.18

TRML Tourmaline Bio Inc

About

Feed

News

Sentiment

Earnings

Fundamentals